Corvus Pharmaceuticals, Inc. 8-K

What Happened

• Corvus Pharmaceuticals, Inc. (CRVS) filed a Form 8-K on May 7, 2026 to announce and furnish a press release reporting its financial results for the quarter ended March 31, 2026 and its financial position as of that date. The press release is furnished as Exhibit 99.1 to the 8‑K. The filing was signed by Chief Financial Officer Leiv Lea.

Key Details

• Filing date: May 7, 2026; Quarter covered: Q1 ended March 31, 2026.
• Item reported: 2.02 (Results of Operations and Financial Condition) — press release contains the quarterly results and business update.
• Exhibit included: 99.1 (press release); the cover page interactive data file is included in Inline XBRL (Exhibit 104).
• Authorized signatory: Leiv Lea, Chief Financial Officer, signed the Form 8-K.

Why It Matters

• This 8-K signals Corvus has released its latest quarterly earnings and a corporate update; investors should review the furnished press release (Exhibit 99.1) for details on revenue, earnings or losses, cash position, and any pipeline or business developments that could affect the company’s outlook. The filing itself confirms the company has publicly disclosed its Q1 2026 results and financial condition.